12:00 AM
 | 
Feb 06, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ampion: Preliminary Phase Ib data

Preliminary data from patients with moderately severe OA of the knee in the expansion phase of the double-blind, Australian Phase Ib AIK trial showed that Ampion significantly reduced overall pain score by 41% from baseline to 30 days post-injection (p=0.016),...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >